The role of AI for drug discovery in healthcare

Artificial intelligence (AI) in drug discovery involves using advanced algorithms and machine learning models to analyse complex biological data. Traditionally, drug discovery has been a time-consuming and costly endeavour. AI accelerates this process by predicting how different compounds will interact with targets in the human body, identifying potential drug candidates more efficiently.

The use of AI in drug discovery offers several notable advantages:

AI algorithms can process vast datasets rapidly, identifying potential drug candidates in a fraction of the time required by traditional methods.

By streamlining the initial stages of drug discovery, AI reduces the financial burden associated with research and development.

AI enables the development of treatments tailored to individual genetic profiles, enhancing therapeutic efficacy.

Machine learning models improve the precision of predictions regarding compound interactions, leading to higher success rates in clinical trials.

A recent study demonstrated that phase 1 trials for AI-discovered drugs have achieved success rates between 80 to 90 per cent, which is significantly higher than the historical industry averages of 40 to 65 per cent.

Pharmaceutical companies are harnessing AI at every stage of the drug discovery and development process:

Machine learning models forecast how a drug will perform in humans, identifying potential side effects and efficacy issues early in the development process.

AI examines patient data to identify suitable candidates for clinical trials, increasing the likelihood of successful outcomes.

AI assists in ensuring that new drugs meet regulatory standards by analysing data and documentation for compliance, reducing the time to market.

The US Food and Drug Administration has noted a significant rise in drug application submissions incorporating AI components.

AI is transforming the drug discovery industry by introducing innovative approaches:

AI analyses extensive datasets to uncover patterns and relationships, leading to the identification of novel drug targets and therapeutic approaches.

Once deemed too time-consuming and pricey, by using AI pharmaceutical companies can now explore medicines for rare diseases.

Pharmaceutical companies are increasingly partnering with AI firms to leverage specialised expertise, fostering innovation and maintaining competitiveness in a rapidly evolving landscape.

As technology continues to advance, the role of AI in drug discovery and development is poised to expand. According to Bekryl Market Analysts, AI has the potential to save over USD 70 billion in the drug discovery process by 2028.